Vaxcyte (PCVX) Cash from Financing Activities (2019 - 2026)

Vaxcyte (PCVX) has 8 years of Cash from Financing Activities data on file, last reported at $601.6 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $601.6 million, up 79159.95% year-over-year; the trailing twelve-month figure through Mar 2026 was $602.8 million (down 63.04% YoY), and the FY2025 annual result was $2.0 million, down 99.92% from the prior year.
• Cash from Financing Activities grew to $601.6 million in Q1 2026 per PCVX's latest filing, from $2.4 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $1.5 billion in Q3 2024 and troughed at -$3.7 million in Q3 2025.
• A 5-year average of $267.9 million and a median of $48.6 million in 2023 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2025 and 2026: Cash from Financing Activities slumped 100.24% in 2025, then soared 79159.95% in 2026.
• A 5-year view of Cash from Financing Activities shows it stood at $656.6 million in 2022, then sank by 99.58% to $2.7 million in 2023, then soared by 79.41% to $4.9 million in 2024, then plunged by 50.93% to $2.4 million in 2025, then soared by 24882.68% to $601.6 million in 2026.
• Business Quant data shows PCVX's Cash from Financing Activities at $601.6 million in Q1 2026, $2.4 million in Q4 2025, and -$3.7 million in Q3 2025.